GlassScriptPhysician profile
Aneeqa A Lone
NPI 1265441273
$3,229.39
in general payments reported to CMS, 2019-2025
25 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $265 · 2021: $204 · 2022: $319 · 2023: $245 · 2024: $246 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,841.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $483.49 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $387.12 | 2019-2025 | Breztri |
| E.R. Squibb & Sons, L.L.C. | $272.79 | 2019-2024 | Eliquis |
| Lilly USA, LLC | $244.79 | 2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $214.56 | 2019-2024 | |
| Axsome Therapeutics, INC. | $212.19 | 2025 | Auvelity |
| Novo Nordisk INC | $205.69 | 2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $160.12 | 2019-2023 | |
| Kestra Medical Technology Services, INC. | $141.37 | 2024-2025 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $117.88 | 2025 | Dupixent |
| Abbott Laboratories | $108.88 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.23 | 2019 | |
| Philips North America LLC | $90.00 | 2022 | |
| Exact Sciences Corporation | $77.15 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $68.02 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $66.17 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.88 | 2025 | Caplyta |
| Chiesi USA, INC. | $43.62 | 2020-2023 | Cleviprex |
| Medicomp INC | $37.76 | 2025 | Telepatch Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.57 | 2019 | |
| Astellas Pharma US INC | $27.31 | 2025 | Veozah |
| Insightec,INC | $21.51 | 2025 | Exablate |
| Xeris Pharmaceuticals, INC. | $20.33 | 2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $18.00 | 2025 | Trelegy Ellipta |
| Inari Medical, INC. | $16.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aneeqa Lone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.